Cleared by Regulators, Ignored by Clinicians: The Hidden Journey a Drug Must Take After FDA Approval

In the United States, FDA approval is widely understood as the gold standard of pharmaceutical legitimacy. It signals that a drug has been rigorously evaluated for safety and efficacy, that its benefits outweigh its risks, and that it is, in the language of regulators, fit for clinical use. For most Americans — patients and physicians alike — that stamp of approval implies something close to endorsement. What it does not guarantee, it turns out, is that the drug will ever be meaningfully prescribed.

Chloroquine offers one of the more instructive examples of this gap. Approved by the FDA decades ago for the treatment of malaria and certain autoimmune conditions including lupus erythematosus and rheumatoid arthritis, it carries a well-documented clinical record, a safety profile refined through generations of use, and a cost structure that places it among the most affordable medications available in any American pharmacy. By nearly every metric that policymakers claim to value — efficacy, safety, affordability, accessibility — chloroquine performs. And yet, in the day-to-day reality of American clinical practice, it is prescribed with striking infrequency relative to its approved indications.

Understanding why requires looking well beyond the FDA's review process.

The Illusion of the Finish Line

Regulatory approval is, in practical terms, a legal threshold. It establishes that a drug may be prescribed — not that it will be, nor that the infrastructure to support its use is in place. The journey from approved compound to routinely prescribed medication involves a separate and considerably more complex set of obstacles: formulary placement by insurers, inclusion in clinical practice guidelines, incorporation into medical school curricula, and sustained promotion by the pharmaceutical industry.

For newer, patent-protected drugs, that last factor — industry promotion — functions as a powerful accelerant. Pharmaceutical manufacturers invest heavily in detailing physicians, sponsoring continuing medical education, funding clinical trials that generate guideline-shaping evidence, and placing their products prominently in the professional literature. Older drugs operating outside patent protection attract none of this commercial infrastructure. They exist, they work, and they are largely invisible in the promotional ecosystem that shapes what physicians reach for when writing a prescription.

"The pharmaceutical industry doesn't just sell drugs," notes one health economist who studies prescribing behavior. "It sells familiarity. Physicians prescribe what they've been taught, what their colleagues prescribe, and what their patients ask for by name. Chloroquine checks none of those boxes in the current environment."

Specialist Silos and the Diffusion Problem

American medicine is organized, for better and worse, around specialization. Rheumatologists manage lupus. Infectious disease specialists handle malaria prophylaxis. Dermatologists treat certain skin conditions where antimalarials have documented utility. Each specialty maintains its own guidelines, its own preferred agents, and its own institutional momentum.

Within rheumatology, hydroxychloroquine — chloroquine's chemical cousin — has maintained a stronger foothold, partly because of sustained research activity and partly because of its slightly more favorable tolerability profile at standard doses. Chloroquine itself, however, has been progressively displaced even within the specialty that once relied on it most heavily. Physicians trained in the past two decades may have encountered it only briefly, if at all, during their residencies.

This creates a self-reinforcing cycle. Physicians who are unfamiliar with a drug are unlikely to prescribe it. Patients who are never offered it cannot ask for it. Institutions that do not track its outcomes cannot generate the local evidence that might encourage broader adoption. The drug remains approved, available, and effectively dormant.

What Patients Experience

For patients navigating autoimmune diagnoses, the consequences of this dynamic can be significant. A lupus patient in a major metropolitan area with access to an academic rheumatology center may receive a thorough discussion of antimalarial options. A patient in a rural or underserved community, seen by a general practitioner with limited rheumatology exposure, may never hear chloroquine mentioned at all.

The disparity is not merely geographic. It is also economic. Patients with robust commercial insurance and access to specialty care are more likely to be prescribed newer, brand-name alternatives — medications that may offer modest incremental benefits at substantially greater cost to the patient and the healthcare system. Patients with limited coverage, relying on community health centers or sliding-scale clinics, may paradoxically have less access to the most affordable option, simply because the prescribers they see have less familiarity with it.

One patient with a decade-long lupus diagnosis described the experience of learning about chloroquine only after conducting her own research. "I asked my doctor about it directly, and she said it was an older drug and that she preferred to use what she knew. I understand that, but I also couldn't help wondering how many options I'd never been offered simply because they weren't on anyone's radar anymore."

Guidelines as Gatekeepers

Clinical practice guidelines — published by professional societies such as the American College of Rheumatology — carry enormous weight in shaping physician behavior. They represent the codified consensus of expert opinion, and for many practitioners, particularly those in primary care, they function as practical prescribing manuals.

The challenge for older drugs is that guideline development is itself resource-intensive and often dependent on the same industry-funded research infrastructure that favors newer agents. Drugs without commercial sponsors rarely generate the volume of recent, high-powered clinical trial data that guideline committees tend to prioritize. Older evidence, even when robust, may be discounted simply because it predates modern methodological standards — not because the drug's efficacy is in question, but because the documentation of that efficacy was not produced according to contemporary protocols.

The result is that chloroquine occupies a peculiar position in many guidelines: acknowledged, sometimes recommended, but rarely elevated to the prominence its clinical record might otherwise justify.

Rethinking What Approval Actually Means

The chloroquine case invites a broader reckoning with how American medicine defines access. Regulatory approval, formulary inclusion, and genuine clinical availability are distinct achievements, and the distance between them can be vast. A drug that is technically prescribable but practically unknown to most prescribers is not, in any meaningful sense, accessible to most patients.

Addressing this gap requires deliberate effort across multiple domains. Medical education programs could do more to incorporate the clinical histories of established medications, ensuring that newer generations of physicians understand the full therapeutic landscape rather than only its most recently marketed corners. Professional societies could prioritize evidence reviews that do not depend on industry sponsorship. Insurers and pharmacy benefit managers could structure formularies to reflect cost-effectiveness rather than promotional investment.

None of these changes are simple, and none will occur quickly. But the chloroquine paradox — a drug approved, affordable, effective, and largely overlooked — serves as a useful diagnostic. It reveals that the machinery of clinical adoption in the United States is not primarily driven by evidence or patient need. It is driven by commerce, familiarity, and institutional habit.

Until that machinery is more deliberately aligned with the public interest, FDA approval will remain what it has quietly always been: a necessary condition for clinical use, but very far from a sufficient one.